6:25 PM
 | 
May 05, 2017
 |  BioCentury  |  Finance

Next in line

WuXi NextCODE's $75 million series B could fuel path to IPO

WuXi NextCODE Genomics Inc. could be the final New WuXi Life Science Ltd. subsidiary to head for an IPO.

NextCODE, one of three New WuXi subsidiaries, announced May 1 that it raised $75 million in a series B round co-led by Temasek and Yunfeng Capital, with participation from Amgen Ventures and 3W Partners.

“We’re hoping that this financing and maybe one additional one will be the last round before we eventually...

Read the full 341 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >